Inhibition of HMGCR, which equates to a one standard deviation reduction in LDL-C levels, was notably connected with a decrease in the likelihood of developing VTE (OR: 0.994, 95% CI: 0.988–1.000, P = .033) and DVT (OR: 0.995, 95% CI: 0.992–0.998, P = .002). The gene discussed is HMGCR; the disease is deep vein thrombosis.